Carbonyl stress and diabetic complications.
Advanced glycation irreversibly and progressively modifies proteins over time and yields the advanced glycation end-products (AGE). AGEs are thought to contribute to the development of atherosclerosis and of diabetic and uremic complications. Their inhibition has thus become a therapeutic goal. In this article, we discuss the role of various reactive carbonyl compound (RCOs) in the genesis of AGEs, postulate the existence of "carbonyl stress" in complicated diabetes and, finally, discuss therapeutic perspectives.
Miyata
Toshio
T
Institute of Medical Sciences, Department of Medicine, Tokai University School of Medicine, Bohseidai Isehara, Kanagawa, Japan. t-miyata@is.icc.u-tokai.ac.jp
Ishikawa
Naoyoshi
N
van Ypersele de Strihou
Charles
C
D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000097:blood / Q000502:physiology*; D006801:Humans; D018384:Oxidative Stress / Q000502:physiology*
D017127:Glycation End Products, Advanced